



## Renounceable Pro-Rata Rights Issue – Closure, Acceptances and Shortfall

**Melbourne, Australia, 24 February 2014:** Australian biopharmaceutical company Immuron Limited (ASX: IMC) is pleased to announce that its renounceable pro-rata rights issue made pursuant to the Prospectus dated 21 January 2014 to raise approximately \$9.66 million (before expenses) on the basis of eleven (11) new fully paid shares in the Company for every six (6) fully paid Shares, at an issue price of 0.5 cents (\$0.005) (the Rights Issue), closed on 21 February 2014.

The Company has received entitlement acceptances in respect of 368,128,158 Shares, leaving a shortfall of 1,563,617,244 Shares. The total amount raised from these entitlement acceptances is \$1,840,640.79.

As the Rights Issue is fully underwritten by Patersons Securities Limited (the Underwriter), the Company has issued a shortfall notice to the Underwriter under the terms of the Underwriting Agreement, for the remaining 1,563,617,244 shortfall Shares, amounting to \$7,818,086.22.

“With our financing now drawing to a conclusion, we are excited to embark on the next stage of the Company’s development,” said Immuron CEO Amos Meltzer. “Having funds available to progress in earnest the Company’s strategy, we are working intensively, to commence our Phase 2 trials for NASH. There is an increasing focus both on the large prevalence of this disease and on the disturbing lack of any available treatments for it. The prospect of a successful outcome in our NASH trials is expected to focus many pharmaceutical companies and investors on Immuron during this exciting period.”

“In parallel, we continue to expand the Travelan franchise and we are progressing our *Clostridium difficile* pre-clinical program. All of these initiatives should add significant value to Immuron and its shareholders.”

**Contact:**

Amos Meltzer  
Chief Executive Officer  
+61 (0)437 587 680

---

### About Immuron Limited

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron technology platform products all have a very high safety profile. Immuron’s current products and product candidates target infectious diseases of the gastrointestinal tract and chronic diseases. Immuron has an on-market product, Travelan, for preventing travellers’ diarrhoea. Immuron also has a phase 2 product candidate for the treatment of inflamed fatty liver disease, known as Non-Alcoholic Steato hepatitis or NASH. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel) and Monash University (Australia).